共 50 条
- [41] Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumorsJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):Shitara, KoheiSatoh, TarohIwasa, SatoruYamaguchi, KenseiMuro, KeiKomatsu, YoshitoNishina, TomohiroEsaki, TaitoHasegawa, JunKakurai, YasuyukiKamiyama, EmiNakata, TomokoNakamura, KotaSakaki, HayatoHyodo, Ichinosuke
- [42] Preliminary results from the Phase I part of a first-in-human Phase I/II study of HH2853, an EZH1/2 inhibitor, in patients with relapsed/refractory non-Hodgkin lymphomas or advanced solid tumorsCANCER RESEARCH, 2023, 83 (08)Fan, ZhengfuWang, JinFang, MeiyuPatrick, JohnstonHan, TunSommerhalder, DavidGong, JifangYang, JilongYang, YunMunoz, JavierSong, YuqinLi, ZhimingLi, Xian'anMa, QiuyingHan, JinmingShen, LinZhu, Jun
- [43] A phase I, multicenter, open-label, first-in-human study to evaluate MEDI0680, an anti-programmed cell death-1 antibody, in patients with advanced malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Infante, Jeffrey R.Goel, SanjayTavakkoli, FatemehMarshall, ShannonRobbins, Paul B.D'Angelo, GinaGribbin, Matthew JosephKarakunnel, Joyson JosephNaing, Aung
- [44] AVZO-021-1001: A first-in-human open-label, multicenter phase I/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumorsANNALS OF ONCOLOGY, 2024, 35 : S405 - S405Dowlati, A.Richardson, D. L.Lorusso, P.Spira, A. I.Bashir, B.Hirmand, M.Mehta, M.Patel, M. R.
- [45] A first-in-human phase I study of ATG-031, anti-CD24 antibody, in patients with advanced solid tumors or B-cell non-Hodgkin lymphomas (PERFORM).JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Fu, SiqingPiha-Paul, Sarina A.Singh, ShivaniPeng, JingKeenan, Bridget P.Mei, Jay M.Lynch, KevinLi, LingSong, MingZhang, Xiaojing
- [46] Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Ra Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical StudyDERMATOLOGY AND THERAPY, 2023, 13 (10) : 2357 - 2373Wynne, Christopher JohnCole, AlexandraLemech, CharlotteWang, GuoqinZhang, YuChen, BenchaoWang, MaxLi, BaiyongXia, MichelleSinclair, Rodney
- [47] Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical StudyDermatology and Therapy, 2023, 13 : 2357 - 2373Christopher John WynneAlexandra ColeCharlotte LemechGuoqin WangYu ZhangBenchao ChenMax WangBaiyong LiMichelle XiaRodney Sinclair
- [48] Preliminary biomarker and pharmacokinetic analysis from the completed dose escalation part of the first-in-human Phase I study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF-A, in patients with advanced solid tumorsEUROPEAN JOURNAL OF CANCER, 2016, 69 : S133 - S133Dawson, K.Feurstein, D.Fiedler, U.Kuster, K.Bez, M.Schreiner, S.Turner, D.Mehr, K. TadjalliStumpp, M.Harstrick, A.Baird, R.Omlin, A.Middleton, M.Rodon, J.Zitt, C.
- [49] Anti-PD-1/TGF-βRII bispecific antibody fusion protein LBL-015 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose-escalation studyJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Li, QunZhao, WeiWang, WeiChen, PoNiu, ZuoxingNi, ShuqinLuo, SuxiaQiao, JunjingWang, MingxiLi, YongHe, YanLiu, TaoLi, TaoCai, ShengliLi, Jin
- [50] Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC)JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Morris, J. C.Shapiro, G. I.Tan, A. R.Lawrence, D. P.Olencki, T. E.Dezube, B. J.Hsu, F. J.Reiss, M.Berzofsky, J. A.